Search alternatives:
significant protective » significant positive (Expand Search), significant potential (Expand Search), significant proteomic (Expand Search)
protective decrease » progressive decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
significant protective » significant positive (Expand Search), significant potential (Expand Search), significant proteomic (Expand Search)
protective decrease » progressive decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
-
1581
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1582
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1583
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1584
-
1585
-
1586
-
1587
-
1588
-
1589
-
1590
-
1591
-
1592
-
1593
-
1594
-
1595
-
1596
-
1597
-
1598
-
1599
-
1600